Older women unlikely to benefit from HPV vax

A new study concludes that women over the age of 40 are unlikely to benefit from an HPV vaccine.

Researchers tracked the experiences of 9,000 Costa Rican women ages 19 to 97 years, screening them for HPV infections, which can trigger cervical cancer. The rate of newly detected infections plunge from 35 percent for women 19 to 25 to 13.5 percent for women over the age of 42. Typically those infections cleared up without treatment.

"Because the HPV vaccine can only prevent infections, and these women are not getting that many new infections, the potential benefit of HPV vaccination among older women is very limited," says Dr. Ana Cecilia Rodríguez, the lead author.

- check out the study abstract
- here's the report from the New York Times

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.